Transforming Growth Factor Beta 1 drives a switch in connexin mediated cell-to-cell communication in tubular cells of the diabetic kidney by Hills, C. E. et al.
 1 
Transforming Growth Factor Beta 1 drives a switch in connexin mediated cell-to-cell 
communication in tubular cells of the diabetic kidney 
 
*Hills CE1, *Price GW1, Wall MJ2, Kauffman TJ2, Tang SC3, Yiu WH3, Squires PE1 
 
 
1. Joseph Banks Laboratories, Green Lane, University of Lincoln, Lincoln, UK 
2. School of Life Sciences, Gibbet Hill, University of Warwick, Warwick, UK 
3. Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary 
Hospital, Hong Kong, China  
 
*Joint 1st author 
 
 
 
 
 
 
 
 
 
 
 
Corresponding author 
 
Dr Claire Hills 
Joseph Banks Laboratories 
University of Lincoln 
Lincoln 
LN6 7DL 
chills@lincoln.ac.uk 
01522 886918  
 2 
 
Abstract  
 
Aims/Hypothesis: Changes in cell-to-cell communication have been linked to several secondary 
complications of diabetes, but the mechanism by which connexins affect disease progression in 
the kidney is poorly understood. This study examines a role for glucose-evoked changes in the 
beta1 isoform of transforming growth factor (TGFβ1), on connexin expression, gap-junction 
mediated intercellular communication (GJIC) and hemi-channel ATP release from tubular epithelial 
cells of the proximal renal nephron.  
Methods: Biopsy material from patients with and without diabetic nephropathy was stained for 
connexin-26 (CX26) and connexin-43 (CX43). Changes in expression were corroborated by 
immunoblot analysis in human primary proximal tubule epithelial cells (hPTECs) and model 
epithelial cells from human renal proximal tubules (HK2) cultured in either low glucose (5mmol/L) ± 
TGFβ1 (2-10ng/ml) or high glucose (25mmol/L) for 48h or 7days. Secretion of the cytokine was 
determined by ELISA.  Paired whole cell patch clamp recordings were used to measure junctional 
conductance in control versus TGFβ1 treated (10ng/ml) HK2 cells, with carboxyfluorescein uptake 
and ATP-biosensing assessing hemi-channel function. A downstream role for ATP in mediating the 
effects of TGF-β1 on connexin mediated cell communication was assessed by incubating cells with 
ATPγS (1-100µM) or TGF-β1 +/- apyrase (5 Units/ml). Implications of ATP release were measured 
through immunoblot analysis of interleukin 6 (IL-6) and fibronectin expression.  
Results: Biopsy material from patients with diabetic nephropathy exhibited increased tubular 
expression of CX26 and CX43 (P<0.01, n=10), data corroborated in HK2 and hPTEC cells cultured 
in TGFβ1 (10ng/ml) for 7days (P<0.001, n=3). High glucose significantly increased TGFβ1 
secretion from tubular epithelial cells (P<0.001, n=3). The cytokine (10ng/ml) reduced junctional 
conductance between HK2 cells from 4.5±1.3nS in control to 1.15±0.9nS following 48h TGFβ1 and 
to 0.42±0.2nS after 7days TGFβ1 incubation (P<0.05, n=5).  Acute (48h) and chronic (7day) 
challenge with TGFβ1 produced a carbenoxolone (200µM)-sensitive increase in 
carboxyfluorescein loading, matched by an increase in ATP release from 0.29±0.06μM in control to 
1.99±0.47μM after 48hr incubation with TGFβ1 (10ng/ml; P<0.05, n=3). TGF-β1 (2-10ng/ml) and 
ATPγs (1-100µM) increased expression of IL-6 (P<0.001 n=3) and fibronectin (P<0.01 n=3). The 
effect of TGF-β1 on IL-6 and fibronectin expression was partially blunted when preincubated with 
apyrase (n=3).   
Conclusion: These data suggest that chronic exposure to glucose-evoked TGFβ1 induce an 
increase in CX26 and CX43 expression, consistent with changes observed in tubular epithelia from 
patients with diabetic nephropathy. Despite increased connexin expression, direct GJIC 
communication decreases, whilst hemichannel expression/function and paracrine release of ATP 
increases, changes that trigger increased levels of expression of interleukin 6 and fibronectin. 
Linked to inflammation and fibrosis, local increases in purinergic signals may exacerbate disease 
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progression and highlight connexin mediated cell communication as a future therapeutic target for 
diabetic nephropathy 
 
Keywords:  diabetic nephropathy, tubular epithelia, TGFβ, connexin, bio-sensing, hemi-channels, 
gap-junctions, ATP, inflammation, fibrosis. 
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Introduction 
 
Diabetic nephropathy (DN) is the single commonest cause of entry into the renal replacement 
programme, and with the incidence of the disease doubling in the past decade, it now accounts for 
approximately 50% of patients presenting with end-stage renal failure [1]. Associated with both 
inflammation and fibrosis [2-3], understanding the mechanism by which glucose evoked changes 
in TGF-β instigate these phenotypic and morphological changes in the kidney, is essential in 
establishing novel therapeutic strategies for the arrest and/or prevention of the disease.  
 
In diabetic nephropathy, for cells to function efficiently and adapt appropriately in times of stress, 
they must not only interact with each other, but also with their immediate environment. Cells 
communicate with their neighbours via direct gap junction intercellular communication or through 
hemichannel mediated paracrine signalling [4-5]. Cells utilise a class of membrane bound proteins 
called connexins (CX), which cluster into a hexameric structure enabling formation of a trans-
membrane pore more commonly termed a connexon [6]. These connexons, alternatively known as 
hemi-channels; align with those on adjacent cells and ‘dock’ to form a gap junction. This junction 
facilitates the transmission of metabolic and electrical signals directly between cells, enabling cells 
to entrain their activity and synchronise tissue function. In the absence of neighbouring partners, 
uncoupled hemi-channels permit local paracrine release of nucleotides, including adenosine 
triphosphate (ATP) and its metabolites (ADP, AMP and adenosine) [4][6].  
 
Regulation of connexin synthesis and activity is critical to cell function and a number of diseases 
can be attributed to changes in expression/function of these important proteins including ischemia 
[7], inflammation [8] and both renin induced and essential hypertension [9-10]. In diabetes, 
hyperglycaemia and subsequent altered connexin expression has proved critical in the 
development and progression of secondary micro-vascular complications, with glucose decreasing 
gap-junction conductance and disrupting cellular homeostasis in a variety of cell types [11-15]. 
Glucose-evoked changes in gap-junction conductance and hemi-channel activity have been linked 
to the pathology of multiple micro-vascular complications of diabetes [12-19], and there is now 
considerable evidence to suggest that connexins represent a potential therapeutic target in the 
treatment of secondary complications of the disease [20-21]. Evidence that connexin expression is 
linked to renal damage [20-22], has led to suggestions that both hemi-channels and gap junctions 
may represent future therapeutic targets for the treatment of diabetic nephropathy (DN).  
 
Of the 21 known mammalian connexins, nine isoforms are expressed within the human kidney 
[reviewed in 23]. Whilst studies on renal vasculature have attributed a role for connexins in the 
regulation of blood pressure [9-10], we still lack a basic understanding of the effects of connexin 
 5 
mediated cell communication in the tubular epithelia. Furthermore, we know nothing as to how 
connexin mediated cell communication may contribute to the pathology of the diabetic kidney.  
 
Tubulointerstitial fibrosis represents the key underlying pathology of diabetic nephropathy with 
progression linked to loss of renal function and entry into End Stage Renal Failure [2]. A 
consequence of multiple morphological and phenotypic changes, the glucose-dependent beta-1 
isoform of the pro-fibrotic cytokine Transforming Growth Factor (TGF-β1) has been demonstrated 
to be instrumental to this series of events [24].  In the current study we present histological 
evidence that demonstrates for the first time, that the expression of key isoforms CX26 and CX43 
are markedly upregulated in biopsy material obtained from patients with DN. We investigate the 
effects of glucose-evoked changes in profibrotic TGF-β1 on expression of predominant tubular 
connexin isoforms 26 and 43 and the implications that these changes have for cell-to-cell 
communication and subsequent downstream phenotypic changes in human proximal tubule cells. 
Understanding the contribution of tubular connexin-mediated cell-to-cell communication in the 
pathogenesis of diabetic nephropathy will help identify potential intervention routes for future 
treatment. 
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Methods 
 
Materials 
Human primary proximal tubule epithelial cells (hPTECs) and human derived proximal tubule 
kidney (HK2) epithelial cells were both obtained from ATCC. Tissue culture supplies were 
purchased from Invitrogen (Paisley, UK). Immobilon P membrane was from Millipore (Watford, UK) 
and enhanced chemoluminescence from Amersham Biosciences (Amersham, UK). Antibodies 
Smad2 and Smad3 are monoclonal antibodies that were obtained from Cell signaling Technology ( 
Danvers, MA, USA). Small interfering RNA (siRNA) was obtained from Santa Cruz (Santa Cruz, 
CA, USA).  For western blot analysis, CX26 and IL6 antibodies were obtained from Abcam 
(Cambridge, UK) and fibronectin from R&D Systems (Abingdon, UK), whilst CX43 antibody was 
obtained from Santa Cruz . For immunohistochemistry anti-CX26 was obtained from (Santa Cruz, 
CA, USA) and anti-CX43 (Sigma-Aldrich,MO, USA). Recombinant human TGF-β1, glucose, 
apyrase and lipofectamine were obtained from Sigma (Poole, UK), as were all other general 
chemicals. The anti-TGF-β1 ELISA was from R&D Systems. ATP biosensors were from Sarissa 
Biomedical Ltd (UK) and fluorodishes from WPI (Hertfordshire, UK). 
 
Staining of tissue 
Renal biopsies from patients with biopsy-proven diabetic nephropathy (DN) (mean age 55; mean 
DM duration: 6.2yrs; mean HbA1C: 7.2%; mean serum creatinine: 464 µmol/L; mean proteinuria: 
5.80 g/24h) were selected for this study. Normal portions of renal tissues removed from 5 
nephrectomy specimens for the treatment of renal carcinoma (mean age 61; mean serum 
creatinine: 87.8 µmol/L) were used as control. For immunohistochemistry, we included 2 types of 
samples that were obtained from renal biopsy of diabetic patients with DN (disease group, n=10), 
and from the normal portion of nephrectomized specimen removed from patients with renal 
carcinoma (control group, n=6). The staining protocol is described previously [25]. Briefly, paraffin-
embedded renal sections (4um) were de-paraffinized, rehydrated and subjected to microwave-
based antigen retrieval in 10mM citric buffer solution, followed by quenching in 1% hydrogen 
peroxide solution and blocking in 2% BSA solution. Each section was stained overnight with either 
anti-CX26 (Santa Cruz Biotechnology, San Cruz, CA) 1:50 or anti-CX43 (Sigma-Aldrich, St. Louis, 
MO) 1:100, antibodies and subsequently incubated with DAKO EnVision+ System-HRP labeled 
polymer antibodies (Dako, Carpinteria, CA). Rabbit IgG was incubated with both DN and control 
renal section as isotype-matched negative control. The immuno-complex was visualized using 
DAB substrate and counterstained with hematoxylin. Quantitative analysis was measured by 
Image-Pro Plus 6.0 and presented as a value of integrated optical density (IOD).  
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Tissue culture 
 
Model cell line 
Human kidney (HK2) cells are a proximal tubular cell (PTC) line derived from normal kidney. The 
cells are immortalized by transduction with human papilloma virus 16 (HPV-16) E6/E7 genes and 
are mycoplasma free. Human kidney (HK2) cells (passage 18-30) were maintained in 
DMEM/Hams F12 medium, supplemented with 10% FCS wt/vol, glutamine (2mmol/l) and EGF 
(5ng/ml), and cultured at 37°C in a humidified atmosphere with 5% CO2. Prior to treatment, cells 
were transferred to DMEM/F12 low glucose (5mmol/l) for 48h as described previously [26]. Cells 
were serum-starved overnight before incubating in TGF-β1 (2–10ng/ml), glucose (25mmol/l), 
conditioned media or L-glucose (25mmol/l) for 48h. To determine a role for glucose-evoked 
changes in TGF-β1 over chronic incubation periods, cells were treated with TGF-β1 (10ng/ml) for 
7days. For ATP experiments cells were incubated in non-hydrolysable ATPγS (1-100µM) for 48h or 
7days with or without the ATP diphosphohydrolase apyrase (5 Units/ml) 
 
Human proximal tubule epithelial cells 
Primary human proximal tubule epithelial cells (hPTECs) were maintained in a renal epithelial cell 
basal medium obtained from ATCC, supplemented with 0.5% FCS wt/vol, Triiodothyronine (10nM), 
rh EGF (10ng/ml), Hydrocortisone Hemisuccinate (100ng/ml), rh Insulin (5µg/ml), Epinephrine 
(1µM), Transferrin (5µg/ml), L-Alanyl-L-Glutamine (2.4mM). Cells were cultured at 37°C in a 
humidified atmosphere with 5% CO2. Prior to treatment, cells were serum-starved overnight before 
incubating in TGF-β1 (10ng/ml) for 7days.  
 
Cytoskeletal staining of HK2 cells 
At 80% confluence, cells were fixed with 4% paraformaldehyde. After blocking, the nuclear stain 
DAPI (1mmol/l) was added for 3min. Cells were then incubated for 1h at 25°C with tetramethyl 
rhodamine isothiocyanate (TRITC)-conjugated phalloidin, diluted at 1:100, in PBS-Triton. Cells 
were visualized using a fluorescence microscope (Axiovert 200; Carl Zeiss, Welwyn Garden City, 
UK). 
 
Quantification of TGF-β1 
Fraser et al [27-28] previously reported that exposure of HK2 cells to high glucose triggers increased 
secretion of TGF- β1. Secretion of the cytokine in our model system was confirmed ahead of 
experiments where cells were incubated in conditioned media. HK2 cells were cultured in 5mmol/l 
glucose containing media for 48h prior to overnight serum starvation. Cells were stimulated for 7days 
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with glucose (25mmol/l) under serum-free conditions and total TGF-β1 measured by specific 
enzyme-linked immunosorbent assay (ELISA) of cell culture supernatant collected from growth-
arrested HK2 cells. Active TGF-β1 is measured directly and latent TGF-β1 measured following acid 
activation of samples. This assay has <1% cross-reactivity for TGF-β2 and TGF-β3. TGF-β1 
concentration was normalized to mg/ml of protein. Data were obtained as pico-grams of TGF-β1 per 
milliliter per mg of protein. 
 
Immunoblotting 
Cytosolic proteins were prepared and separated by gel electrophoresis and electro-blotting on to 
Immobilon P membranes as described previously [29]. Membranes were probed with specific 
polyclonal antibodies against anti-CX43 and anti-CX26 at dilutions of 1:200 and 1:400 respectively. 
For assessment of Smad activity, membranes were probed with anti-pSmad2 and anti-pSmad3 at 
dilutions of 1:1000. For assessment of IL-6 and Fibronectin, membranes were probed with 
antibodies at dilutions of (1:1000) and (1:1000) respectively. 
 
Smad 2 and Smad 3 SiRNA knockdown 
Cells were grown to 40% confluence in six-well plates. Transfection of siRNAs was carried out 
using lipofectamine as described previously [30]. To confirm a role for Smad2/3 in mediating the 
downstream effects of TGF-β1 on CX26 and CX43 expression, HK2 cells were stimulated with 
TGF-β1 (10ng/ml) for 48h post Smad2/3 knockdown. Negative controls included non-transfected 
cells, lipid alone, and scrambled siRNA. Smad2 and Smad3 knockdown were confirmed by 
Western blot analysis. 
 
Electrophysiology 
Described previously [31], cells cultured on glass cover-slips were transferred to the recording bath 
and perfused (2ml/min) with physiological saline solution composed of (mM): 127 NaCl, 1.9 KCl, 
1.2 KH2PO4, 26 NaHCO3, 1 MgCl2, 2CaCl2 and 10 D-Glucose bubbled with 95% O2/ 5 % CO2 
and maintained at 32⁰C. Cells were visualized (x600 magnification) using IR-DIC optics (Olympus 
BX51W1 microscope and Hitachi CCD camera). Paired whole cell patch-clamp recordings were 
made from neighboring cells using thick-walled borosilicate (Harvard) glass pipettes (3-8MΩ) 
containing (mM): 135 potassium gluconate, 7 NaCl, 10 HEPES, 0.5 EGTA, 10 phosphocreatine, 2 
MgATP, 0.3 NaGTP (∼300 mOSM, pH7.2). Recordings were made using an Axon Multiclamp 
700B amplifier (Molecular Devices) and digitized at 20 kHz (Axon Digidata 1440a). Data 
acquisition and analysis was performed using pClamp (v10, Axon, Molecular Devices). 
 
Once paired whole cell recordings were established, series resistance (10-16MΩ) was monitored 
and compensated appropriately. If the series resistance markedly changed during the recording, 
then the data was excluded from analysis. Electrical coupling between recorded cells was 
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confirmed by observing a change in membrane potential in one cell following injection of 
hyperpolarizing and depolarizing current steps in the other cell. At the end of recordings, the 
electrodes were lifted off the cells and identical current steps were injected to ensure that there 
was no cross talk between electrodes. 
 
 
Measuring junctional conductance 
Input resistance and coupling coefficients (ratio of membrane potential changes between the two 
cells) were determined from membrane potential responses following the injection of a series of 
hyperpolarizing and depolarizing current steps into each cell. The junctional conductance (Gj) was 
then calculated using the following equation: Gj12 = R1k12/((R1R2)-(R1k12)2), where R1 and R2 
are the input resistances of the 2 cells and k12 is the coupling coefficient [28-29]. Estimates for 
junctional conductance were calculated in both directions between pairs of cells. 
 
Carboxyfluorescein loading 
Fluorodishes were plated with HK2 cells in DMEM/F12 low glucose (5mmol/l) for 48h. Cells were 
serum starved overnight before culturing +/- TGF-β1 (10ng/ml) for 48h or 7days. Cells were 
exposed to a Ca2+-free BSS (zero CaCl2 + EGTA (1mM)), plus carboxyfluorescein (200 µM) for 10 
min, followed by a 10 min period in Ca2+-containing BSS, plus carboxyfluorescein (200 µM). The 
dishes were then washed with control Ca2+-containing BSS to remove excess dye. In a separate 
series of experiments, cells were pre-incubated with carbenoxolone in Ca2+-free BSS for 30min 
and carbenoxolone was applied throughout the loading protocol described above. Cells were 
imaged using a Cool Snap HQ CCD camera (Roper Scientific) with Metamorph image software 
(Universal Imaging Corp., Marlow, Bucks, UK). Quantification of dye loading was performed using 
ImageJ. A region of interest (ROI) was drawn around individual cells (15 in each dish) and mean 
pixel intensity calculated. All values have been corrected for background fluorescence in a 
representative ROI. 
 
ATP biosensor measurements  
Biosensors consist of enzymes trapped within a matrix around a Pt or Pt/Ir (90/10) wire [32] 
Biosensors were cylindrical with an exposed length of ~2 mm and diameter of ~ 50 µm. Two types 
of sensor were used in this study:  Firstly, null sensors, possessing the matrix but no enzymes, to 
control for non-specific electro-active interferents and ATP biosensors which consist of the 
entrapped enzymes glycerol kinase and glycerol-3-phosphate oxidase [33]. Glycerol (2 mM) was 
included in all solutions as a co-substrate for ATP detection.  HK2 cells were grown on coverslips 
in DMEM/F12 low glucose (5mmol/L) for 48h. Cells were serum-starved overnight before culturing 
+/- TGF-β1 (10ng/ml) for 48h or 7days. Cells were then transferred to a chamber containing 
balanced salt solution (BSS) composed of (mM): (137 NaCl, 5.4 KCl, 0.8 MgSO4, 0.3 Na2HPO4, 
 10 
0.4 KH2PO4, 4.2 NaHCO3, 10 HEPES and 5 glucose, pH7.4), with CaCl2 (1.3mM) perfused at a 
rate of 6ml/min (37°C) for 10 min to acclimatise. Before ATP measurements were made, cells were 
pre-loaded with ATP to increase the signal [34]. Hemi-channels were opened with a 5 min 
perfusion of Ca2+-free BSS (+ EGTA (1mM)), cells were then incubated with 10 mM ATP in Ca2+-
free BSS for 10 mins before the hemi-channels were closed by the addition of Ca2+-containing 
BSS. Following ATP loading, ATP and null bio-sensors were bent so that the surface of the sensor 
was parallel to the coverslip, and placed just above the cells. After a stable baseline was 
established, Ca2+-free BSS was perfused over the cells to open the hemi-channels and release 
ATP.  A standard solution containing ATP (10μM) was used to calibrate against a standard curve 
and ensure biosensor sensitivity. Recordings were acquired at 1 kHz with a Micro CED (Mark2) 
interface using Spike (Vs.6.1) software. 
 
Analysis 
Autoradiographs were semi-quantified by densitometry (TotalLab 2003; NonLinear Dynamics, 
Durham, NC USA). Non-stimulated, low-glucose control was normalized to 100% and data from all 
other experiments compared to this. Statistical analysis was performed using a one-way ANOVA 
test with Tukey’s multiple comparison post-test or a t-test. Data are expressed as mean±SEM, with 
‘n’ denoting the sample number. A p-value <0.05 signified statistical significance. 
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Results 
 
Connexin expression is up-regulated in tubular epithelia from patients with diabetic 
nephropathy 
Glucose-evoked changes in both gap-junction conductance and hemi-channel activity have been 
linked to the development and progression of multiple micro-vascular complications of diabetes 
[14-19]. However, despite being highly expressed in the proximal tubule [23], our knowledge of 
connexin expression in the diabetic kidney is severely limited. Using integrated optical density 
(IOD) readings to quantify immunohistochemical staining we evaluated expression of the connexin 
isoforms CX26 (Fig 1a and b) and CX43 (Fig 1c and d) in renal biopsies from patients with and 
without DN. In non-disease control, CX26 was predominantly expressed in renal tubules, with 
relatively weak staining in the glomeruli (Fig 1a panels C and D). In biopsy material from patients 
with DN (Fig 1a panels A and B), tubular expression of CX26 expression was up regulated to 
102700±6226 compared to control 21030±4727 (Fig 1 b; n=10 p<0.01).  Similarly, tubular 
expression of CX43 was significantly increased in patients with DN (Fig 1c panels A and B) to 
116300±5908, compared to non-diseased control (Fig 1c panels C and D) at 21460±10920 (Fig 1 
d; n=10 p<0.01).  Rabbit IgG was incubated with both DN and control renal section as an isotype 
matched negative control (Fig 1e) 
 
Glucose stimulates increased TGF-β1 in human proximal tubule cells 
In diabetes, hyperglycaemia instigates multiple downstream signalling pathways, responsible for 
both inflammation and the accumulation of fibrotic material in the tubulointersitium [2-3].  Whilst 
more than a dozen fibrogenic factors affect renal function, it is widely recognised that glucose-
evoked changes in pro-sclerotic cytokine TGF-β1 and its downstream Smad signalling cascade, 
represents the predominant pathway in orchestrating renal fibrosis [35]. ELISA on supernatant 
fractions from glucose treated HK2 cells confirmed glucose-evoked changes in TGF-β1 in cells of 
the human proximal tubule (Fig 2a) [36]. Cells were cultured in 5mM glucose for 48h prior to being 
starved of serum overnight and stimulated for 7days with low (5mmol/l) or high D-glucose 
(25mmol/l) under serum-free conditions. In high glucose, total TGF-β1 secretion increased 
(994.4±43.6 pg/ml) compared to the 5mmol/l low glucose control (334±14.9 pg/ml; n = 3; p<0.01) 
(Fig 2a). Differences in TGF-β1 were only detected following acidification of the samples, 
suggesting that TGF-β1 was produced in its latent form. L-glucose (25mmol/l) failed to increase 
TGF-β1 secretion and was used as an osmotic control (OC; Fig 2a).  
 
Non-stimulated HK2 cells exhibit a cobblestone morphology characteristic of proximal tubular 
epithelial cells (Fig 2, panel b, control). Following activation of latent TGF-β1 by repeat freeze-thaw 
cycles of 7day conditioned (25mmol/l) media [26], 48h treatment of cells with this media altered 
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gross morphology in favor of an elongated fibrous phenotype, comparable to that observed with 
TGF-β1 (10ng/ml; Fig 2 panel b). Morphological changes at 48h were accompanied by actin 
reorganization, with F-actin filaments forming dense peripheral stress fibers in conditioned media 
and TGF-β1, compared to the diffuse trans-cellular network of actin that spans the cytosol under 
control conditions (Fig 2 Panel c). Exposure to 25mmol/l D-glucose alone, failed to alter either cell 
morphology or cytoskeletal architecture (Fig 2 Panels b and c respectively). 
 
Glucose-evoked TGF-β1 has a bi-phasic effect on CX26 and CX43 at 48h and 7days in 
human proximal tubule cells. 
HK2 cells were cultured in 5mM glucose for 48h prior to being serum starved overnight and then 
incubated for 48h in conditioned media (25mmol/l D-glucose), high D-glucose (25mmol/l), TGF-β1 
(2-10ng/ml), or an osmotic control (L-glucose 25mmol/l). Activated conditioned media significantly 
reduced CX26 (Fig 3a) and CX43 (Fig 3b) expression to 44.3±2.6% and 53.3±2.0% of control 
(5mmol/l) (n=3; p<0.001). D-glucose alone (25mmol/l) failed to alter CX26 expression, however 
induced a small significant change in CX43 expression. Immunoblot analysis confirmed that 48h 
incubation with TGF-β1 (2-10 ng/ml) decreased CX26 expression to 72.7±13.3%, 71.6±4.8%, and 
58.3±5.7% at 2, 4 and 10ng/ml compared to control (Fig3c; p<0.001, n=4), whilst CX43 levels 
decreased to 61.2±10.4%, 49.5±6.1%, and 48.1±3.8% compared to control (Fig3d; p<0.001, n=4).  
 
In contrast, chronic incubation of both HK2 and human primary proximal tubule cells (hPTECS) 
with TGF-β1 (10ng/ml) for 7days (Fig 4) matched elevated expression in biopsy material isolated 
from patients with nephropathy (Fig 1). At 7days, non-stimulated hPTEC cells exhibit a 
cobblestone morphology characteristic of proximal tubular epithelial cells (Fig 4a, panel A, control). 
Incubation of hPTECS for 7days with TGF-β1 altered gross morphology towards that of an 
elongated fibrous phenotype (10ng/ml; Fig 4a panel B). Immunoblot analysis confirmed that 
chronic incubation with TGF-β1 (10ng/ml) for 7days significantly increased the expression of CX26 
and CX43 to 203.9±7.5% (Fig4b) and 151.1±7.1% (Fig4c) of control respectively (p<0.001, n=4) in 
HK2 cells. Chronic incubation of hPTECs with TGF-β1 (10ng/ml) for 7days significantly increased 
the expression of CX26 and CX43 to 309±39% (Fig4d) and 303±10.4% (Fig4e) of control 
(p<0.001, n=4).  
 
TGF-β1 regulates CX26 and CX43 expression via a classical SMAD2/SMAD3 pathway in HK2 
cells 
TGF-β1 and its downstream Smad and non-Smad signalling mediators, represent the main 
pathway orchestrating fibrosis in the diabetic kidney [reviewed in 35]. However, it is not clear as to 
how TGF-β1 mediates its effects on CX26 and CX43. To determine a classic; canonical (Smad 
signalling) role for glucose evoked changes in TGF-β1 (Fig2a) in regulating CX expression, SMAD 
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signalling in HK2 cells was confirmed prior to investigating a role for SMAD2/3 in mediating the 
effects of TGF-β1 on expression of CX26 and CX43. 
 
HK2 cells were cultured in 5mmol/l glucose for 48h prior to overnight serum starvation. Cells were 
then stimulated between 5min and 6h with TGF-β1 (10ng/ml) and Smad activity assessed via 
immunoblotting (Fig5). Data confirmed that TGF-β1 optimally phosphorylates Smad2 (Fig 5a) and 
Smad3 (Fig 5b) at 1h. Prior to delineating the role for Smad2/3 in TGF-β1 evoked changes in 
connexin expression, transient transfection of HK2 cells with Smad2 and Smad3 siRNA was 
performed at 48h and 96h to assess knockdown efficiency. At 48h, knockdown of Smad2 (Fig 5c) 
and Smad3 (Fig 5e) achieved 59.2±2.9% and 70.1±7.2% efficiency compared to control (p<0.001, 
n=3). At 96h, transfection efficiency was 62.9±7.3% for Smad2 (Fig 5d) and 59.8±11.2% for 
Smad3 (Fig 5f) compared to control (p<0.001, n=3). Scrambled siRNA and transfection reagent 
alone had no effect.  
 
In HK2 cells, TGF-β1 (10ng/ml, 48h) reduced CX26 and CX43 expression to 75.7±3.4% and 
66.7±5.5% of control (Fig 5g and h). To determine if this loss in expression was Smad-dependent, 
cells were transiently transfected with either Smad2 or Smad3 siRNA for 48h, prior to treatment 
with TGF-β1 (10ng/ml). TGF-β1 induced loss in expression was negated post Smad2/Smad3 
knockdown, restoring CX26 expression to 87.5±4.7% and 113.6±5.4% (Fig 5 g) respectively, as 
compared to TGF-β1 treatment alone (24.34±3.4%). Similarly, Smad2 and Smad3 knockdown 
restored CX43 expression to 100.6±11.7% and 129±51.5 % respectively (Fig 5h), compared to 48h 
TGF-β1 treatment alone (33.3±5.5%) (p<0.001, n=3).  
 
TGF-β1 evokes an acute and chronic reduction in junctional conductance. 
To assess the functional consequence of altered connexin expression, we used paired whole cell 
patch clamp recordings to measure the junctional conductance between TGF-β1 treated HK2 cells 
(Fig 6a).  Cells were cultured overnight in 5 mmol/l glucose without serum. Cells were then 
stimulated for 48 h or 7 days with TGF-β1 (10ng/ml) under serum-free conditions and gap junction 
intercellular communication (GJIC) assessed against non-stimulated control cells. In control, the 
junctional conductance was 4.5 ± 1.3nS (n = 5, Fig 6b). TGF-β1 significantly decreased junctional 
conductance at both 48h (1.15 ± 0.9nS; p<0.05, n = 5) and 7days (0.42 ± 0.2nS; p<0.05, n=5).  
 
TGF-β1 increases hemi-channel activity in HK2 cells  
Hemi-channels can be opened experimentally by removing extracellular calcium. When open, 
uptake of the membrane impermeant dye carboxyfluorescein, acts as a functional measure of 
hemi-channel number/activity [34]. Following 48h in low (5mmol/l) glucose, HK2 cells were serum 
starved overnight before a further 48h (Fig 7a and b) or 7day period (Fig 7c and d) +/- TGF-β1 
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(10ng/ml) under serum-free conditions.  After 48h in TGF-β1, removing extracellular calcium 
(10min) significantly increased carboxyfluorescein (200µM) uptake compared to control (378 ± 
33% p<0.001, n=3; 15 cells per dish; Fig 7a/b,). The increase was negated by pre-incubation with 
the hemi-channel blocker carbenoxolone (200µM; 110 ± 5.4% of control). At 7 days, dye uptake 
increased to 430 ± 18% compared to control (Fig 7c/d). Pre-incubation with carbenoxolone 
(200µM) significantly reduced dye uptake in both control and TGF-β1 treated cells to 41±2.7% and 
64±2.6% respectively (p<0.001, n=3).  
 
TGF-β1 increases ATP release from HK2 cells. 
We used ATP biosensors to measure the real time release of ATP from HK2 cells treated for 48h 
+/- TGF-β1 (10ng/ml; Fig 8a). Biosensors recorded linear changes in ATP over a concentration of 
0.1-100μM (Fig 8b/c and see [34]). In non-stimulated control cells the concentration of ATP 
released was 0.29 ± 0.06 µM (Fig 8d/f), which  was significantly increased in TGF-β1 treated cells 
to 1.99 ± 0.47µM (Fig 8e/f, p<0.05, n=3).  
 
Glucose evoked changes in ATP drive increased expression of inflammatory markers 
Interleukin 6 in HK2 cells 
Recent studies have confirmed a link between renal connexin expression and tubule inflammation 
[21][37]. Elevated levels of nucleotides and altered connexin expression has been linked to 
inflammation and downstream fibrosis in multiple tissue types [38-44]. Having confirmed that 
glucose evoked changes in TGF-β1 drive increased expression of both CX26 and CX43, changes 
accompanied by increased hemichannel mediated ATP release, immunoblot analysis was used to 
assess the implications of TGF-β1 and ATP as downstream mediators of a glucose-evoked 
response on expression of inflammatory and fibrotic markers Interluekin-6 (IL-6) and fibronectin 
respectively. 
 
HK2 cells were cultured in 5mM glucose for 48h prior to being serum starved overnight and then 
incubated for either 48h or 7days in TGF- β1 (2-10ng/ml). Immunoblot analysis confirmed that at 
48h incubation with TGF- β1 (2-10 ng/ml), IL-6 expression was increased to 137.7±13.9%, 
244.9±33.4% and 286.3±26.0% as compared to control (Fig9a p<0.001, n=4). Fibronectin 
expression increased to 129.5±11.7%, 176.4±30.4%, and 210±22.7% at 2, 4 and 10ng/ml 
compared to control respectively (Fig9b; p<0.001, n=4). At 7days incubation, IL-6 expression was 
increased to 690±88.9% as compared to control (Fig9c; p<0.05, n=3). Similarly, fibronectin 
expression increased to 188±12.8%, at 10ng/ml TGF- β1 as compared to control (Fig9d; p<0.05, 
n=3). These data confirm that TGF- β1 evokes increased expression of IL-6 and fibronectin in HK2 
cells at both acute and chronic time periods. 
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To delineate a downstream role for ATP in mediating these-glucose evoked changes, HK2 cells 
were in the first instance incubated with non-hydroylsable ATPγS (1-100µM) for 48h. Expression of 
IL-6 (Fig10a) and fibronectin (Fig10b) was assessed by immunoblotting. ATPγS (1-100µM) evoked 
a significant increase in expression of IL-6 expression to 204.8±32.1%, 206.0±26.3% and 
227.3±14.8% at 1, 10 and 100 µM compared to control respectively (Fig10a; p<0.001, n=4) and of 
fibronectin expression to 274.5±47.2%, 350.4±23.1% and 433.0±81.1% at 1, 10 and 100 µM as 
compared to control respectively (Fig10b; p<0.001, n=4). 
  
Lastly, the link between TGF-β1 induced changes in ATP and altered expression of IL6 and 
fibronectin, was ascertained by incubating HK2 cells for 48hrs in TGF- β1 (10 ng/mL) +/- 
ATP diphosphohydrolase; apyrase (5 Units/ml). As expected TGF- β1 evoked an increase in both 
IL-6 and fibronectin to 274.1±35.5% (Fig10c), and 201.50±3.7% (Fig10d) respectively as 
compared to control (p<0.01 n=3). These changes were negated in part in the presence of 
apyrase, with expression reduced to 181.6±6.3%, and 156.7±27.6% for IL-6 and fibronectin 
respectively. Incubation of apyrase alone failed to exert any significant effect on expression.  
 
To further delineate a role for ATP in mediating glucose-evoked changes at chronic intervals, HK2 
cells were incubated with ATPγS (1-100 µM) for 7 days. Expression of IL-6 (Fig11a) and fibronectin 
(Fig11b) was assessed by immunoblotting. ATPγS(1-100 µM) evoked a significant increase in 
expression of IL-6 expression to 174.0±8.4%, 233.9±11.3% and 260.0±10.8% at 1, 10 and 100 µM 
compared to control respectively (Fig11a; p<0.001, n=4). Fibronectin expression also increased 
to 305.4±22.61%, 358.6±17.7% and 417.3±25.69% at 1, 10 and 100 µM as compared to control 
respectively (Fig11b; p<0.001, n=4). As with 48hrs, HK2 cells were also incubated for 7 days in TGF-
β1 (10 ng/mL) +/- the ATP diphosphohydrolase; apyrase (5 Units/ml). As before, TGF-β1 evoked an 
increase in both IL-6 and fibronectin to 431.5±34.49% (Fig11c), and 262.4±42.5% (Fig11d) 
respectively as compared to control (p<0.05 n=3). These changes were negated in part in the 
presence of apyrase, with expression reduced to 190.9±47.92%, and 105.8±28.02% for IL-6 and 
fibronectin respectively. Incubation of apyrase alone failed to alter protein expression.  
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Discussion 
 
Diabetes is the single commonest cause of entry into the renal replacement therapy programme 
and accounts for half of patients presenting with end-stage renal disease (ESRD) [1]. 
Approximately 21% of deaths in type1 diabetes and 11% of deaths in type2 diabetes are 
attributable to loss of renal function associated with diabetic nephropathy [43], a multifaceted 
complication which encompasses structural and functional disturbances including glomerular 
hyper-filtration, mesangial expansion, and interstitial fibrosis [2]. As a major underlying pathology 
of diabetic nephropathy, tubulointerstitial fibrosis develops under sustained hyperglycaemia, when 
early injury activates secretion of inflammatory mediators, infiltration of inflammatory cells, 
increased fibrotic deposition and overall loss of cell structure, function and integrity. [3]. Whilst 
current treatments focus on regulation of blood glucose and blood pressure [44], the ability to 
correct tubular inflammation and subsequent downstream fibrosis represents an unmet clinical 
need.  
 
In diabetic nephropathy, the progression of tubular injury is associated with a number of 
morphological and phenotypic events [35][36]. Pivotal to these is the early loss of the adhesion 
protein epithelial (E)-cadherin, which forms part of the multi-protein adherens junction, linking cell-
cell contact to the actin cytoskeleton and various signaling molecules [47]. Co-localized with E-
cadherin at the sites of cell-cell contact [48], connexins oligomerise into hexameric hemi-
channels/connexons that can form gap-junctions connecting the cytoplasm of adjoining cells 
[reviewed in 49]. Intercellular adhesion is a pre-requisite for gap junction formation. In the absence 
of neighboring binding partners, uncoupled hemi-channels permit local paracrine release of 
adenosine triphosphate (ATP) [4][6]. We previously reported that acute glucose evoked loss of 
cadherin mediated cell-cell coupling affected direct dye transfer between epithelial cells of the 
human proximal tubule [36]. The implications of this impaired adhesion and loss of dye transfer 
remain unresolved.  
 
The present study correlates altered connexin expression to altered cell function in proximal 
tubular epithelial cells of the diabetic kidney. Novel histological evidence, suggests that expression 
of both CX26 and CX43 are significantly upregulated in tubules from renal biopsy material isolated 
from patients with diabetic nephropathy. These findings are further supported by observations that 
CX26 and CX43 exhibit increased expression in both our cell model and human primary proximal 
tubule cells at 7days incubation with TGF-β1. Interestingly, in the present study, the effect of TGF-
β1 on connexin expression appears temporally dependent. Acute 48h incubation with 
glucose/TGF-β1 significantly reduced Smad2/3-dependent CX26 and CX43 expression in HK2 
cells. However, chronic incubation with the same stimuli for 7days increased CX26 and CX43, a 
trend consistent with data from renal biopsy material isolated from patients with DN and with recent 
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reports that CXs appear to be upregulated in chronic kidney disease [20-21][49]. To delineate the 
functional consequences of this biphasic response, we used paired whole cell patch clamp 
recordings to directly measure how TGF-β1 affected GJIC. At both 48h and 7day incubation with 
the cytokine, junctional conductance was significantly reduced as compared to control. This 
counterintuitive finding can be explained by considering the relationship between cell-cell coupling 
and the ability of connexons to align and form functional gap-junctions [4-5][50]. Following acute 
challenge with high glucose and TGF-β1, connexin expression decreases providing less protein to 
form connexins and ultimately gap junctions. As expected, GJIC decreased. Contrary to this, 
chronic 7day incubation in high glucose/TGF-β1 increased the expression of both CX26 and CX43. 
This shift in expression should mean that there is more protein to form connexons and thus gap-
junctions, however, junctional conductance was again reduced.  This finding can be explained by 
drawing on our previous work, which suggests that glucose-evoked changes in TGF-β1 drives a 
loss of cell-to-cell adhesion [36]. With impaired cell-cell adhesion, connexons are unable to dock 
with similar hexameric units on adjacent cells and gap junctions fail to form [4-5]. In the absence of 
suitable binding partners, connexons exist as stand-alone pores. These hemi-channels are known 
to release nucleotides, in particular, ATP, as well as other small molecules and ions [6]. Under 
normal circumstances small amounts of ATP released into the microenvironment may provide a 
paracrine mechanism to maintain cell-to-cell communication. However, in chronic high 
glucose/TGF-β1, as associated with diabetes, up-regulation of connexin-mediated hemi-channels 
may overload this local diffusible route of communication. Several studies have suggested that 
there is a strict relationship between hemi-channel release of ATP and activation of purinergic 
receptors on neighbouring cells and that this may play a role in mediating the underlying pathology 
of various disease states [42][51-53]. Having confirmed that in both acute and chronic time points, 
glucose/TGF-β1 evoked changes in CX expression are paralleled by reduced GJIC, we wanted to 
determine if hemi-channel activity increased as a compensatory mechanism to maintain cell-to-cell 
communication. Carboxyfluorescein is a membrane impermeant dye that has been previously used 
to assess hemi-channel opening in a variety of cell types [31]. An increase in carbenoxleone-
sensitive dye uptake suggested that the number and/or activity of hemi-channels was elevated in 
cells cultured in TGF-β1 for 48h and 7days. To confirm that the increase in channel opening 
correlated to a change in purinergic signalling, we used biosensors and demonstrated that 
increased hemichannel activity in TGF-β1 treated cells was matched by a significant increase in 
ATP release. 
 
Recent studies confirm a link between hemi-channel mediated ATP release and progression and 
development of inflammation and fibrosis in multiple tissue types [38-41], including the diabetic 
kidney [42]. The connexin isoforms CX37 and CX40 have been highlighted as anti-inflammatory, 
whilst CX43 has been linked to inflammation [21]. Studies in the CX43 +/- mouse demonstrate 
reduced monocyte infiltration and reduced interstitial fibrosis, whilst administration of either a CX43 
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antisense or inhibition of CX43 with the Gap26 mimetic peptide, partly negate the inflammatory 
and fibrotic changes as seen in the interstitium of a mouse model of CKD [21]. Preclinical studies 
addressing a role for ATP in the pathology of diabetic nephropathy are somewhat limited, perhaps 
reflecting a lack of suitable mouse models of this disease. Nevertheless, activation of the NLRP3 
inflamasome and subsequent activation of proinflammatory markers interleukin 1 beta (IL-1β) and 
interleukin 18 (IL18) have been linked to elevated extracellular ATP levels and enhanced 
purinergic signaling [54-58]. Once in the extracellular environment, these interleukins produce an 
array of inflammatory proteins including TNF-α and IL-6 that are instrumental in the pathology of 
tubular inflammation and fibrosis [59-60]. Associated with abberant increased synthesis of the 
extracellular matrix (ECM) remodelling, ATP has also been suggested to be play a key role in ECM 
remodelling and subsequent fibrosis [55]. Studies by Solini et al confirmed that exogenous 
application of ATP to rat mesangial cells, triggered a concentration dependent increase in the ECM 
markers, fibronectin, collagen IV, laminin and pro-fibrotic TGF-β [55]. These changes were 
negated by pre-incubation of high glucose with apyrase, a calcium-activated membrane-bound 
enzyme that catalyses the hydrolysis of ATP to AMP and inorganic phosphate, thereby 
deactivating ATP [55]. In the current study, our novel data suggests, that cells shift from GJIC to 
hemi-channel mediated ATP release as they attempt to maintain cell-to-cell communication and 
overall function. Interestingly, with increased hemi-channel mediated ATP release having been 
linked to fibrosis in multiple disease states [38-39], it is likely that this mechanism may contribute to 
tubular injury through increased ATP-driven fibrosis. Certainly our data would suggest that in an 
attempt to maintain epithelial cell-to-cell communication in late stage nephropathy, imbalance in 
connexin expression/function could actually exacerbate disease progression, with increased 
hemichannel mediated ATP release driving increased expression of proinflammatory IL-6 and 
profibrotic fibronectin. Whilst our understanding of the complex interplay between connexins, 
nucleotide release and downstream purinergic signalling in hyperglycaemia remains rudimentary, it 
is clear that connexins offer a viable future target in the therapeutic control and treatment of this 
chronic debilitating metabolic condition and command further future investigation. 
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Figure legends 
Fig. 1: CX26 and CX43 expression is upregulated in biopsy material isolated from patients 
with proven nephropathy. Immunohistochemical staining of CX26 (Fig 1a) and CX43 (Fig 1c) in 
human renal tissue from patients with biopsy proven diabetic nephropathy is shown in panels A 
and B and for non-diabetic control subjects in panels C and D. Isotype-matched negative control 
(Fig 1e is shown in non-diabetic controls (Panel A) and diabetic nephropathy (panel B). 
Magnification: 400X. Quantitative analysis of CX26 (Fig 1b) and CX43 (Fig 1d) staining was 
performed by Image Pro Plus 6.0 software; IOD, Integrated Optical Density. **P<0.01 compared 
with control. 
 
Fig. 2: Glucose-evoked increases in TGF-β1 stimulate morphological changes associated 
with early tubular injury. HK2 cells were cultured in low glucose (5mmol/l), high glucose 
(25mmol/l) or an osmotic control (OC, L-glucose; 25mmol/L). The supernatant was removed and 
TGF-β1 secretion quantified by ELISA (Fig 2a). Secreted TGF-β1 was activated by a repeat 
freeze-thaw procedure of conditioned media. Phase contrast microscopy (Fig 2b) and TRITC 
conjugated phalloidin (Fig 2c) assessed cell morphology and cytoskeletal organization respectively 
in low glucose (5mmol/l), conditioned media (25mmol/l), TGF-β1 (10ng/ml) and high glucose 
(25mmol/l) for 48h.   
 
Fig. 3: Glucose and TGF-β1 evoke a loss in CX26 and CX43 expression at 48h. HK2 cells 
were cultured in low glucose (5mmol/l, control), conditioned medium (25mmol/l CM), L-glucose 
(OC, 25mmol/l) and high glucose (25mmol/l) (panels a and b) or in low glucose (5mmol/l) with or 
without TGF-β1 (2-10ng/ml) for 48h (panels c and d). Whole-cell abundance of CX26 (Fig 3a & 3c) 
and CX43 (Fig 3b and 3d) were determined by immunoblotting. Representative blots are shown for 
each protein with re-probing for α-tubulin as loading control. Semi-quantification (mean ± SEM) 
was by densitometry, normalized against the non-stimulated low glucose control (100%). Bars 
correspond to associated lanes in the respective blot. Results were from three or more separate 
experiments; *P<0.05, **P<0.01 and ***P<0.001. 
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Fig. 4: TGF-β1 evokes an increase in CX26 and CX43 expression at 7days incubation. HK2 
(Fig 4b and 4c) and hPTEC cells (Fig 4a, d and e) were cultured with or without TGF-β1 (10ng/ml) 
for 7days. Phase contrast morphology of control hPTEC (panel A) and TGF-β1 (10ng/ml) (panel B) 
treated hPTECs  at 7days is shown in Fig 4a 
 
Whole-cell abundance of CX26 (Fig 4b & 4d) and CX43 (Fig 4c and 4e) were determined by 
immunoblotting in HK2 and hPTECs respectively. Representative blots are shown for each protein 
with re-probing for α-tubulin as loading control. Semi-quantification (mean ± SEM) was by 
densitometry, normalized against the non-stimulated low glucose control (100%). Bars correspond 
to associated lanes in the respective blot. Results were from three or more separate experiments; 
*P<0.05, **P<0.01 and ***P<0.001. 
 
Fig. 5: TGF-β1 regulates CX26 and CX43 expression via SMAD2/3 signalling. TGF-β1 
stimulates phosphorylation of SMAD2 (Fig 5a) and SMAD3 (Fig 5b) in HK2 cells. Knockdown of 
both SMAD2 at 48hrs and 96hrs respectively (Fig 5c & 5d) and SMAD3 at 48hrs and 96hrs 
respectively (Fig 5e & 5f) was achieved using siRNA. Representative blots show changes in 
protein for transfection reagent (TR) alone, SMAD siRNA (S2 and S3) and scrambled siRNA (SS) 
versus the same blot stripped and re-probed for α-tubulin as a loading control. HK2 cells were then 
transfected for 48h with either SMAD2 or SMAD3 siRNA. Post transfection, cells were stimulated 
with TGF-β1 (10ng/ml) for 48h and expression of CX26 and CX43 assessed. Whole cell protein 
expression of CX26 (Fig 5g) and CX43 (Fig. 5h) were determined by immunoblotting. 
Representative blots are shown for each protein with re-probing for α-tubulin. Semi-quantification 
(mean ± SEM) was by densitometry, normalized against non-stimulated low glucose control 
(100%). Bars correspond to the associated lanes in the respective blot. Results were from three or 
more separate experiments; ***P<0.001. 
 
Fig. 6: TGF-β reduces junctional conductance between coupled HK2 cells. Panel a, Paired 
whole cell patch clamp recordings from coupled cells in control, cells treated with TGF-β1 (10 
ng/ml) for 48 hours and cells treated with TGF-β1 (10 ng/ml) for 7 days. Hyperpolarizing and 
depolarizing current steps (20 pA, -40 to 40 pA) injected into cell-1 produced voltage responses in 
cell-2 demonstrating electrical coupling. The inset is a micrograph showing electrode positions 
during a recording from coupled cells. Panel b, Graph plotting the mean junctional conductance for 
pairs of cells in control versus cells treated with TGF-β1 (10 ng/ml) for 48h and 7days. The 
junctional conductance is significantly reduced in TGF-β1 treated cells at 48 h (1.15±0.9nS) and 7 
days (0.42±0.2nS) compared to control (4.5±1.3nS; * P<0.05).  
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Fig. 7: TGF-β1 increases hemi-channel dependent dye loading in HK2 cells. 
Carboxyfluorescein (200μM) loading in 48h (Fig 7a and b) and 7day (Fig 7c and d) control and 
TGF-β1 (10ng/ml) treated HK2 cells with and without carbenoxolone (CBX; 200μM). Minimal dye 
loading is visible in control cells at 48h (Fig 7a) and 7days (Fig 7c). There is strong dye loading in 
cells cultured with TGF-β1 at both time points, consistent with an increased number/opening of 
connexin hemi-channels.  Addition of carbenoxolone (200μM) significantly reduced the dye 
loading. Pixel intensity from TGF-β1 treated cells expressed as a percentage of control at 48h (Fig 
7b) and 7days (Fig. 7d) demonstrates that opening of the hemi-channels by removal of 
extracellular calcium (10 min) significantly increases dye uptake at 48 h (378 ± 33%) or 7days (430 
±18%).  Addition of carbenoxolone (200μM) prevented cytokine-evoked changes at both time 
intervals (110±5.4% of control at 48h and 64±2.6% of control at 7days). Pixel intensity was 
recorded for 10 cells in 3 separate experiments; **P<0.01 and ***P<0.001. 
 
Fig. 8: TGF-β1 increases hemi-channel mediated ATP release. Fig 8a, shows the experimental 
recording configuration with both ATP and null sensors (2 mm sensing area) situated horizontally 
above the HK2 cells. Fig 8b, ATP biosensor trace showing responses to different concentrations of 
ATP. Inset, Graph plotting current against ATP concentration (Fig 8c). ATP biosensors show a 
linear response to increasing concentrations of ATP (n = 3 for each point). No changes in baseline 
current were observed on null sensors (data not shown). (Fig 8d and 8e) Representative ATP 
biosensor traces showing the effect of calcium removal following 48h treatment with either control 
(Fig. 8d) or TGF-β1 (10ng/ml; Fig 8e). Cells cultured in TGF-β1 exhibit a discernable release of 
ATP when extracellular calcium is removed whereas there is little or no response in control cells. 
Application of 10 µM ATP at the end of the experiment is used for calibration and shows that the 
biosensor sensitivity was similar for both treatments. Fig 8f, graph plotting the mean data 
demonstrating the effect of TGF-β1 versus control on the amount ATP release following 48h 
incubation.  Cells cultured with the cytokine exhibited a 7fold increase in ATP release compared to 
control (1.99 ± 0.47 µM versus 0.29 ± 0.06 µM; P<0.05). 
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Fig. 9: TGF-β1 upregulates expression of Interleukin-6 and Fibronectin at 48h and 7 days. 
HK2 cells were initially cultured in TGF-β1 (2-10ng/ml) for 48h, ahead of chronic incubation at 
7days in TGF-β1 (10ng/ml). Whole-cell expression of pro-inflammatory IL-6 and pro-fibrotic 
fibronectin were determined by immunoblotting at 48h TGF-β1 incubation (Fig 9a and 9b 
respectively). For chronic treatment, cells were cultured in low glucose (5mmol/l) with or without 
TGF-β1 (10ng/ml) for 7days and whole-cell expression of IL-6 and fibronectin assessed (Fig 9c 
and 9d respectively). Representative blots are shown for each protein with re-probing for α-tubulin 
as loading control. Semi-quantification (mean ± SEM) was by densitometry, normalized against the 
non-stimulated low glucose control (100%). Bars correspond to associated lanes in the respective 
blot. Results were from three or more separate experiments; *P<0.05, **P<0.01 and ***P<0.001. 
 
Fig. 10: ATP drives increased expression Interleukin-6 and Fibronectin at 48hrs and 7 days. 
Glucose evoked changes in TGF-β1 drive altered IL6 and fibronectin expression through 
downstream ATP signaling. HK2 cells were cultured in low glucose (5mmol/l, control) with or 
without ATPγS (1-100µM/ml) for 48h. Whole-cell expression of IL-6 (Fig 10a) and fibronectin (Fig. 
10b) were determined by immunoblotting. Confirmation of a role for ATP in mediating the TGF-β1 
induced response as observed in Fig 9; was determined by incubating cells with TGF-β1 with or 
without Apyrase for 48h. Whole-cell expression of IL-6 (Fig 10c) and fibronectin (Fig 10d) were 
determined by immunoblotting. Representative blots are shown for each protein with re-probing for 
α-tubulin as loading control. Semi-quantification (mean ± SEM) was by densitometry, normalized 
against the non-stimulated low glucose control (100%). Bars correspond to associated lanes in the 
respective blot. Results were from three or more separate experiments; *P<0.05, **P<0.01 and 
**P<0.01. 
 
Fig. 11: ATP drives increased expression Interleukin-6 and Fibronectin at 7 days. 
HK2 cells were cultured in low glucose (5mmol/l, control) with or without ATPγS(1-100µM/ml) for 7 
days. Whole-cell expression of IL-6 (Fig 11a) and fibronectin (Fig. 11b) were determined by 
immunoblotting. To establish a role for ATP in mediating TGF-β1 induced response as observed in 
Fig 9; HK2 cells were incubated with TGF-β1 with or without Apyrase for 7 days and whole-cell 
expression of IL-6 (Fig 11c) and fibronectin (Fig. 11d) assessed. Representative blots are shown for 
each protein with re-probing for α-tubulin as loading control. Semi-quantification (mean ± SEM) was 
by densitometry, normalized against the non-stimulated low glucose control (100%). Bars 
correspond to associated lanes in the respective blot. Results were from three or more separate 
experiments; *P<0.05, **P<0.01 and ***P<0.01. 
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